Newsletter Tool

PM Tracker

Today’s Big News

Jun 27, 2025

After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in

SCOTUS upholds ACA preventive services task force in 6-3 ruling

Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials

FDA removes CAR-T access barrier in move set to boost cancer immunotherapy uptake

UCB plots regulatory filings as Fintepla shows potential to treat a 3rd epilepsy disorder

Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride Month

Featured

After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in

By Fraiser Kansteiner

While concerns over pricing and access to Novo’s Wegovy and Lilly’s Zepbound persist, especially given the sheer number of people who received replicated versions while the meds were in shortage, indulging compounders who continue to sell cheaper copycats en masse is misguided, multiple experts have cautioned.

SCOTUS upholds ACA preventive services task force in 6-3 ruling

By Paige Minemyer

The Supreme Court upheld a key preventive services task force in a 6-3 ruling issued Friday morning.

Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials

By James Waldron

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.

FDA removes CAR-T access barriers in move set to boost cancer immunotherapy uptake

By Angus Liu

The FDA has removed the REMS requirements for currently approved BCMA- and CD19-directed CAR-T therapies and reduced certain post-infusion restrictions.

UCB plots regulatory filings as Fintepla shows potential to treat a 3rd epilepsy disorder

By Kevin Dunleavy

UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could pave the way for its use in another epilepsy condition. A phase 3 trial of Fintepla treating patients with the ultra-rare CDKL5 deficiency disorder has achieved its primary endpoint.

Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset

By Gabrielle Masson

Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 directed therapeutics from Mabwell Bioscience, including a clinical-stage monoclonal antibody for age-related diseases.

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride Month

By Andrea Park

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, with Pride Month nearing its end, the vast majority have acknowledged the celebration in some way.

With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs

By Fraiser Kansteiner

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.

FDA broadens reach of GE HealthCare's amyloid imaging agent Vizamyl in Alzheimer's diagnostics

By Conor Hale

The imaging agent can be used to deliver quantitative assessments such as calculations of amyloid prevalence through FDA-authorized software.

Ocular Therapeutix sharpens focus with retina-centric rebrand

By Nick Paul Taylor

Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli.

Sophia Genetics launches podcast to decode data- and AI-driven medical innovation

By Andrea Park

Alongside its development of artificial intelligence-powered software to analyze huge amounts of genomic, imaging and other healthcare data, Sophia Genetics is now turning to a new medium to explain that work to the masses.

Glaukos nets European green lights for glaucoma surgery micro-stents

By Conor Hale

Glaukos said the approvals were its first under the European Union’s new and more-stringent Medical Device Regulation pathway.

Havas dives 'Beyond the Brief' in campaign emphasizing neurodiversity as the creative future

By Zoey Becker

Merck KGaA executive Renee Connolly and Gen Z recording artist Lola Young joined Havas Health and Creative Networks CEO Donna Murphy at a Cannes Lions panel highlighting neurodivergent minds.

Fierce podcasts

Don’t miss an episode

Resources

Whitepaper

Building Peak Performance Go-to-Market Operations

We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance.

Presented by Blue Matter, strategic consultants in the life sciences

Upcoming Fierce Events

5-2

May-Jul

Fierce Pharma Marketing Awards

Deadline Extended: July 2

8-11

Sep

Fierce Pharma Week

Philadelphia, PA

Sep

Fierce Pharma Marketing Awards Gala

Sheraton Philadelphia Downtown

7-9

Oct

Fierce Biotech Week

Boston, MA

12-13

Nov

Diversity, Equity & Inclusion Forum

Free Virtual Event

View all events

This email was sent to [email protected] as part of the Fierce Life Sciences email list.